Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 296 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR A Better Biomarker for Cancer Immunotherapy? November 3, 2023 Plans for NCI’s Fiscal Year 2019 Budget December 18, 2018 Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence... April 4, 2024 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 Load more HOT NEWS EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... The Nobel Prize in Chemistry 2020 was Awarded “for the Development... Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial,... New targeted treatment for early breast cancer could reduce risk of...
